Cingulate Inc. (CING) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 8.63M USD | Liabilities, Current |
| Cash and equivalents | 28.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.63M | $28.40M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $10.96M | $25.89M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.31M | $10.95M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $5.88M | $6.12M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $6.73M | $8.90M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $5.62M | $9.52M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $4.97M | $12.21M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.54M | $10.04M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $2.04M | $380.93K | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.25M | $1.11M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $10.23M | $52.42K | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $5.73M | $1.99M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $10.99M | $349.83K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.66M | $1.74M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $7.01M | $5.36M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.41M | $9.80M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $923.50K | $8.20M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.63M | $12.61M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.18M | $16.49M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.36M | $1.20M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |